Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression

Asian Journal of Andrology

Volumn 10, Issue 4, 2008, Pages 635-641

  Gao, Qing Zhen ^a   Lu, Jia Ju ^b   Liu, Zi Dong ^a   Zhang, Hui ^b   Wang, Shao Mei ^a   Xu, He ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Cell cycle; Dexamethasone; Extracellular signal regulated kinase 1 2; Prostate cancer

Indexed keywords

CYCLIN D1; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DEXAMETHASONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROSTATIC NEOPLASMS; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 45749147849     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00352.x     Document Type: Article

References (19)

1. Altuwaijri S, Wu CC, Niu YJ, Mizokami A, Chang HC, Chang C. Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells. Asian J Androl 2007; 9: 181-8.
2. He QJ, Yang B, Lou YJ, Fang RY. Contragestazol (DL111-IT) inhibits proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo. Asian J Androl 2005; 7: 389-93.
3. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286: 1358-62.
4. Clark JA, Black AR, Leontieva OV, Frey MR, Pysz MA, Kunneva L, et al. Involvement of the ERK signaling cascade in protein kinase C-mediated cell cycle arrest in intestinal epithelial cells. J Biol Chem 2004; 279: 9233-47.
5. Davis RJ. MAPKs: New JNK expands the group. Trends Biochem Sci 1994; 19: 470-3.
6. Brondello JM, McKenzie FR, Sun H, Tonks NK, Pouysségur J. Constitutive MAP kinase phosphatase (MKP-1) expression blocks G1 specific gene transcription and S-phase entry in fibroblasts. Oncogene 1995; 10: 1895-904.
7. Nupponen N, Visakorpi T. Molecular biology of progression of prostate cancer. Eur Urol 1999; 35: 351-4.
8. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59: 803-6.
9. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999; 59: 279-84.
10. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003; 63: 1981-9.
11. Johnson CS, Hershberger PA, Bernardi RJ, Mcguire TF, Trump DL. Vitamin D receptor: A potential target for intervention. Urology 2002; 60 (3 Suppl 1): 123-30; discussion 130-1.
12. Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, et al. Combination of so-matostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004; 10: 4398-405.
13. Scholz IV, Cengic N, Göke B, Morris JC, Spitzweg C. Dex-amethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter. J Clin Endocrinol Metab 2004; 89: 1108-16.
14. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 2006; 12: 3003-9.
15. Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res 2006; 12: 6012-7.
16. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, et al. Potential mechanism for the effects of dex-amethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001; 93: 1739-46.
17. Li Z, Chen Y, Cao D, Wang Y, Chen G, Zhang S, et al. Glucocorticoid up-regulates transforming growth factor-β (TGF-β) type II receptor and enhances TGF-β signaling in human prostate cancer PC-3 cells. Endocrinology 2006; 147: 5259-67.
18. Dondi D, Maggi R, Scaccianoce E, Martini L, Motta M, Poletti A. Expression and role of functional glucocorticoid receptors in the human androgen-independent prostate cancer cell line, DU145. J Mol Endocrinol 2001; 26: 185-91.
19. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6: 703-6.